Portugal INFARMED

Rozlytrek (Entrectinib) – Public funding evaluation report available; approval of prior assessment request

Original title: Rozlytrek (Entrectinib) | Relatório de avaliação de financiamento público disponível | Deferimento do pedido de avaliação prévia

Portugal INFARMED approved the prior assessment request for Rozlytrek (entrectinib) and made the public funding evaluation report available.

Low obligation Product class Pharmaceuticals Market Access & Reimbursement Portugal PharmaceuticalsReimbursement

Data : 17/07/2026

Dates and deadlines

Applies from

2026-07-17

Regulatory Deadline

July 17, 2026

Read the official source ↗

Published by Portugal INFARMED. HealthSignal links to the original document; the summary above is extracted from the source text.